Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01423
|
|||||
| Drug Name |
Lurtotecan
|
|||||
| Synonyms |
OSI-211; Lurtotecan [INN]; 149882-10-0; UNII-4J1L80T08I; OSI 211; NX 211; GG 211; Gi 147211; 4J1L80T08I; C28H30N4O6; CHEMBL341028; 11H-1,4-Dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8H,14H)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (8S)-; GI-147211C; lurtotecan liposome; AC1L1U8C; SCHEMBL19208; CHEMBL305666; DTXSID30164422; GG-211; ZINC22010625; NX-211; GW-211; BDBM50036130; DB12222; LS-173358; Lurtotecan dihydrochloride; GI 147211C; GG-147211C; GI-147211; GI-147211A; GL-147211C; Liposomal lurtotecan
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Ovarian cancer [ICD11: 2C73] | Discontinued in Phase 2 | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C28H30N4O6
|
|||||
| Canonical SMILES |
CCC1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC6=C(C=C5N=C4C3=C2)OCCO6)CN7CCN(CC7)C)O
|
|||||
| InChI |
InChI=1S/C28H30N4O6/c1-3-28(35)20-11-22-25-18(14-32(22)26(33)19(20)15-38-27(28)34)17(13-31-6-4-30(2)5-7-31)16-10-23-24(12-21(16)29-25)37-9-8-36-23/h10-12,35H,3-9,13-15H2,1-2H3/t28-/m0/s1
|
|||||
| InChIKey |
RVFGKBWWUQOIOU-NDEPHWFRSA-N
|
|||||
| CAS Number |
CAS 149882-10-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 518.6 | Topological Polar Surface Area | 105 | ||
| Heavy Atom Count | 38 | Rotatable Bond Count | 3 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 9 | |||
| XLogP |
0.3
|
|||||
| PubChem CID | ||||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| References | ||||||
| 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004939) | |||||
| 2 | A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method. Comput Biol Med. 2011 Nov;41(11):1006-13. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.